Emerson Electric Co. research snapshot
EMR AI stock analysis currently reads Emerson Electric as a higher-quality industrial automation company, not a deep-value cyclical. Emerson benefits from process automation, control systems, software, power and measurement products, and management focus after years of portfolio reshaping. The July 8, 2026 setup is balanced because the business has durable end-market exposure and strong cash generation, while the stock reference price of $137.91 implies about 31.85x TTM EPS and only a 1.61% dividend yield. The EMR AI stock forecast therefore uses scenario ranges, not a precise price prediction, and treats order growth, margin expansion, software mix, debt reduction, and industrial capex demand as the variables that matter most.
Current price
$137.91
Market cap
$77.24 billion verified market cap
AI score
64 / 100
Rating
High-quality automation franchise with strong software exposure, but valuation already prices in execution
Trend status
Constructive but extended, trading above key moving averages after a strong multi-quarter advance
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Emerson sells automation hardware, controls, measurement, valves, power systems, and industrial software that customers use to run critical process and hybrid operations. | High |
| Moat | Installed base, technical trust, switching costs, software and control-system integration, channel reach, and scale support the moat, though industrial customers still push on price and project timing. | Medium-high |
| Management | Lal Karsanbhai has accelerated portfolio simplification toward automation, but the current test is converting the reshaped portfolio into sustained organic growth and cash returns. | Medium-high |
| Financial trend | FY2025 sales were $18.016 billion and net income attributable to common stockholders was $2.293 billion, with Q2 fiscal 2026 reported net sales of $4.5 billion. | High |
| Valuation | At $137.91, EMR screens near 31.85x TTM EPS, 4.29x sales, 3.83x book value, 24.98x free cash flow per share, and a 1.61% dividend yield. | High |
| Technical trend | The chart remains above medium-term trend references, but the July 7 drop and valuation level make confirmation more important than chasing strength. | Medium |
| Risk level | Main risks are industrial capex slowdown, automation order softness, software integration missteps, leverage after portfolio moves, China and Europe weakness, and multiple compression. | Medium-high |
| AI confidence | Descriptive confidence is high because the financial data is rich and cross-checked. Return confidence is lower because the stock already reflects a favorable automation story. | High data confidence |
| Investment certainty | EMR is a strong franchise, but the current price needs continued margin delivery and order resilience to justify the multiple. | Medium |
EMR AI stock forecast
The EMR AI stock forecast is scenario-based because the market is already valuing Emerson as a premium automation compounder. Using the $137.91 price reference, TTM EPS of $4.33, and the audited three-year model, the mechanical range points to about $69 in a bear case, $103 in a base case, and $138 in a bullish case before dividends. Upside beyond that range needs stronger normalized EPS, higher software mix, and a premium multiple that persists.
$135 to $160 before dividends
More likely if automation orders improve, management lifts margins, software and AspenTech-related exposure grows, free cash flow compounds, and investors keep valuing EMR near a premium industrial multiple.
$100 to $125 before dividends
More likely if earnings grow mid-single digits, free cash flow remains healthy, but the market applies a more normal industrial multiple after the recent stock advance.
$65 to $85 before dividends
More likely if industrial demand slows, project orders weaken, integration benefits disappoint, China or Europe remains soft, debt reduction slows, or investors reprice EMR closer to a cyclical industrial multiple.
EMR AI technical analysis
EMR AI technical analysis is constructive but valuation-sensitive as of the July 8, 2026 data cutoff. The reference quote was $137.91 on July 7, 2026, with intraday range of $136.98 to $141.61 and volume near 2.16 million shares. The setup favors trend discipline because a strong automation narrative can reverse quickly if earnings or order commentary disappoint.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $137.91 | Google Finance listed the latest July 7, 2026 trade reference at $137.91. |
| Immediate support | $136 to $138 | This area brackets the latest intraday low of $136.98 and the close reference. |
| Deeper support | $124 to $128 | This is a practical prior-range zone to monitor if premium industrial multiples compress. |
| Near resistance | $141 to $142 | This range overlaps the July 7 intraday high of $141.61 and is the first level buyers need to reclaim. |
| Upper resistance | $150 to $160 | This range needs sustained EPS upgrades or stronger order momentum because valuation is already above market-average earnings multiples. |
| Moving averages | Use the 50-day and 200-day trend as confirmation filters | A pullback that holds medium-term trend support is healthier than a breakout without order or margin confirmation. |
| Momentum | Positive but vulnerable after a strong run | Momentum should be weighed against earnings quality because high-quality industrials can still derate when orders slow. |
| Volume | 2.16 million shares on the July 7 reference | Rising volume on breaks below support would weaken the trend-following case. |
| Volatility | Watch earnings, order commentary, and industrial PMI data | Automation stocks can move quickly around backlog, margin, and capex-cycle updates. |
| Invalidation | Close below $136, then below $124 | A sustained break below the latest support area would reduce short-term trend confidence. A break below the deeper support zone would challenge the larger premium-multiple thesis. |
EMR AI trading strategy
The EMR AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with order growth, margin delivery, software mix, cash conversion, leverage, and industrial capex data.
Watch for EMR to reclaim $141 to $142 after earnings or order data confirms automation demand, margin expansion, and healthy free cash flow.
A failed reclaim followed by a close below $136 should reduce trend confidence, especially if management points to weaker orders or slower margin progress.
If EMR pulls back toward $124 to $128 without a break in automation demand or cash generation, compare the lower price with normalized EPS and cash conversion.
Do not treat a lower share price as attractive if the pullback is tied to order cancellations, project deferrals, debt pressure, or structural margin weakness.
Track process automation orders, discrete and hybrid demand, AspenTech-related software contribution, gross margin, operating cash flow, net debt, dividend coverage, buybacks, and management guidance.
Position sizing should reflect that EMR is a premium industrial automation stock, not a guaranteed compounder at any price.
Investment research summary
Customers pay Emerson because factories, refineries, life-science plants, power systems, and process operators need reliable measurement, control, automation, software, and service support for mission-critical assets.
The moat comes from installed base, control-system integration, engineering trust, switching costs, domain expertise, channel reach, and scale. It is durable, but not immune to project cycles or customer bargaining power.
The thesis fails if automation demand slows, competitors narrow the technology gap, software integration underdelivers, leverage limits capital returns, or a premium multiple compresses faster than earnings can grow.
Management has reshaped Emerson into a more focused automation company. The next proof point is whether capital allocation, portfolio integration, and margin targets create per-share value rather than only a cleaner story.
Automation sits on a long-term trend toward safer operations, labor productivity, energy efficiency, software-driven control, and industrial data. The offset is that capex cycles, rates, and regional demand still matter.
At $137.91, EMR prices in a strong automation franchise and continued execution. Margin of safety improves if earnings accelerate without multiple expansion, or if the stock pulls back closer to the base-case valuation range while orders remain sound.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| EMR quote reference | $137.91 latest July 7, 2026 trade, intraday range $136.98 to $141.61 | Google Finance EMR quote | July 8, 2026 |
| Market capitalization verification | $77.24 billion calculated from $137.91 x 560.10 million shares | Pineify financial_rigor.py and StockAnalysis EMR statistics | July 8, 2026 |
| Shares outstanding | 560.10 million shares outstanding, rounded market-data figure | StockAnalysis EMR statistics | July 8, 2026 |
| FY2025 revenue | $18.016 billion net sales, cross-checked against StockAnalysis and AlphaQuery | Emerson FY2025 results release | July 8, 2026 |
| FY2025 net income common | $2.293 billion net income attributable to common stockholders, cross-checked against Macrotrends | StockAnalysis EMR financials | July 8, 2026 |
| Cash and equivalents | $1.544 billion fiscal 2025 cash and equivalents, validated against StockAnalysis, Macrotrends, and Emerson 10-Q beginning cash | Emerson fiscal 2026 Q2 Form 10-Q | July 8, 2026 |
| Q2 fiscal 2026 sales | $4.5 billion reported net sales | Emerson Q2 fiscal 2026 results release | July 8, 2026 |
| Valuation snapshot | 31.85x TTM EPS, 3.83x book value, 24.98x free cash flow per share, 1.61% dividend yield | Pineify financial_rigor.py valuation verification | July 8, 2026 |
| Three-scenario model | Bull $138.3, base $103.1, bear $69.3 before dividends using EPS $4.33 and 24x, 20x, 16x terminal P/E cases | Pineify financial_rigor.py three-scenario model | July 8, 2026 |
This EMR AI stock analysis is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell any security. Forecasts are scenario ranges based on available data as of July 8, 2026 and may be wrong if earnings, orders, rates, valuation multiples, or market conditions change.
